Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy

Trends in Pharmacological Sciences 2026 Open access

Read full text
Authors: Rajan Thapa, Jesus Shrestha, Keshav Raj Paudel
DOI: 10.1016/j.tips.2026.01.009
Cited by: 2
References: 15

Abstract

FLT3 mutations drive acute myeloid leukemia (AML) progression through aberrant signaling, making FLT3 inhibition a key therapeutic strategy. Current inhibitors show efficacy, yet resistance and toxicity remain challenges. Emerging approaches, including selective inhibitors, proteolysis-targeting chimeras, and protein degraders, offer enhanced potency, sustained suppression, and combinatorial potential, representing a precision-based advancement in AML treatment.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Protein Degradation and Inhibitors Nuclear Structure and Function

Publication details

Journal / source
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Volume
47
Issue
3
Pages
244–247
Publication date
23 February 2026
Language
EN